摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(7,8,9,10-四氢-5,7,7,10,10-五甲基-5H-苯并[b]萘并[2,3-e][1,4]二氮杂卓-12-基)-苯甲酸 | 172705-89-4

中文名称
4-(7,8,9,10-四氢-5,7,7,10,10-五甲基-5H-苯并[b]萘并[2,3-e][1,4]二氮杂卓-12-基)-苯甲酸
中文别名
——
英文名称
HX600
英文别名
HX 600;4-(5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzo[4,5]cyclohepta[1,2-b]naphthalen-12-yl)benzoic acid;4-(7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzo[4,5]cyclohepta[1,2-b]naphthalen-12-yl)benzoic acid;4-(5,7,7,10,10-Pentamethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid
4-(7,8,9,10-四氢-5,7,7,10,10-五甲基-5H-苯并[b]萘并[2,3-e][1,4]二氮杂卓-12-基)-苯甲酸化学式
CAS
172705-89-4
化学式
C29H30N2O2
mdl
——
分子量
438.569
InChiKey
DLFBCHSYAZBTSS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    589.6±50.0 °C(Predicted)
  • 密度:
    1.17±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    7.4
  • 重原子数:
    33
  • 可旋转键数:
    2
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    52.9
  • 氢给体数:
    1
  • 氢受体数:
    4

SDS

SDS:36fe6810d58e6f8924cdd0a53411b416
查看

制备方法与用途

HX600 是一种合成激动剂,能够与 RXR (Retinoid X Receptor) 异源二聚体复合物结合。它能有效预防因缺血导致的神经元损伤,并且具有良好的口服生物活性。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • PPAR-gamma modulator
    申请人:SANKYO COMPANY, LIMITED
    公开号:US20030134859A1
    公开(公告)日:2003-07-17
    A compound of the following formula or a pharmacologically acceptable salt thereof: 1 wherein A represents a phenyl group or the like, B represents an aryl group or the like, X represents an oxygen atom or the like, and n represents 0 or 1. The compound is a PPAR &ggr; modulator which is a therapeutic agent for retrograde osteoporosis in which excessive differentiation of adipocytes is inhibited and formation and differentiation of osteoblasts from stem cells is facilitated, and for diabetes mellitus without characteristics such as excessive adipogenesis, liver dysfunction, vascular disorders, heart diseases and the like.
    以下化学式的化合物或其药理学上可接受的盐:其中A代表苯基或类似物,B代表芳基或类似物,X代表氧原子或类似物,n代表0或1。该化合物是一种PPAR &ggr; 调节剂,用于治疗逆行性骨质疏松症,通过抑制脂肪细胞的过度分化并促进干细胞向成骨细胞的形成和分化,以及用于糖尿病而不具有过度脂肪生成、肝功能障碍、血管紊乱、心脏疾病等特征。
  • PPAR (GAMMA) MODULATORS
    申请人:Sankyo Company, Limited
    公开号:EP1277729A1
    公开(公告)日:2003-01-22
    [Subject] The present invention has a purpose for providing a PPAR γ modulator which can be a therapeutic agent for retrograde osteoporosis in which excessive differentiation of adipocytes was inhibited and formation and differentiation of osteoblasts from stem cells is facilitated or that for diabetes mellitus without characteristics such as excessive adipogenesis, liver dysfunction, vascular disorders, heart diseases and the like. [Solution] A compound of the following formula or a pharmacologically acceptable salt thereof: wherein A represents a phenyl group or the like, B represents an aryl group or the like, X represents an oxygen atom or the like, and n represents 0 or 1.
    主题 本发明的目的在于提供一种PPAR γ调节剂,该调节剂可作为逆行性骨质疏松症的治疗药物,在逆行性骨质疏松症中,脂肪细胞的过度分化受到抑制,而干细胞的成骨细胞的形成和分化得到促进,或者可作为无过度脂肪生成、肝功能障碍、血管紊乱、心脏病等特征的糖尿病的治疗药物。 [解决方案] 下式化合物或其药理学上可接受的盐: 其中 A 代表苯基或类似物,B 代表芳基或类似物,X 代表氧原子或类似物,n 代表 0 或 1。
  • Methods for inhibiting cell growth
    申请人:Zhao Yi
    公开号:US20090203720A1
    公开(公告)日:2009-08-13
    Cell growth is inhibited and/or cell death is induced in a cell by administering an RXR agonist and an inhibitor of casein kinase 1α. A cell or a tissue can be screened for enhanced susceptibility to cell death or interference with cell growth. Conditions characterized by uncontrolled cell growth or proliferation, such as a cancer, can be treated with inhibitors of casein kinase 1α.
  • [EN] 11-PHENYL-DIBENZODIAZEPINE DERIVATIVES AS RXR-ANTAGONISTS<br/>[FR] DERIVES DE 11-PHENYL-DIBENZODIAZEPINE EN TANT QU'ANTAGONISTES DU RXR
    申请人:NOVARTIS AG
    公开号:WO2004089916A1
    公开(公告)日:2004-10-21
    The present invention relates to novel benzodiazepine compounds exhibiting RXR-antagonist efficacy, for delaying progression of, preventing or treating a condition or disease being associated with RXR-antagonism, in particular selected from diabetes, complication of diabetes such as retinopathy, nephropathy, neuropathy, and hyperlipidemia, obesity, dyslipidemia, and osteoporosis.
    本发明涉及一种新型苯二氮卓类化合物,具有RXR拮抗剂功效,用于延缓、预防或治疗与RXR拮抗作用相关的疾病或病症,特别是包括糖尿病、糖尿病并发症如视网膜病变、肾病、神经病变和高脂血症、肥胖、血脂异常和骨质疏松症。
查看更多